Emerging Treatment Options in Treatment-Resistant Depression and Anxiety Disorders

CNS Spectrums

Volumn 9, Issue S14, 2002, Pages 25-32

  Ishak, Waguih William ^a   Rapaport, Mark H ^a   Gotto, Jennifer G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; DESIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; INOSITOL; LITHIUM; METHYLPHENIDATE; MILNACIPRAN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; PINDOLOL; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROXINE; ZIPRASIDONE;

ANXIETY DISORDER; BRAIN DEPTH STIMULATION; COMORBIDITY; CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; ELECTROCONVULSIVE THERAPY; HUMAN; MAJOR DEPRESSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE STIMULATION;

EID: 11144240027     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900028935     Document Type: Article

References (66)

1. AJ, Rush, Crismon, ML, Toprac, MG, et al. Implementing guidelines and systems of care: experiences with the Texas Medication Algorithm Project (TMAP). J Pract Psychiatry Behav Health. 1999; 5: 75–86.
2. Fava, M, Rush, AJ, Trivedi, MH, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003; 26(2):457–494.
3. World Health Organization. The World Health Report Mental Health: New Understanding, New Hope. Geneva, Switzerland: WHO; 2001.
4. Judd, LL, Akiskal, HS, Maser, JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptomatology in unipolar major depressive disorders. Arch Gen Psychiatry. 1998; 55: 694–701.
5. Rush, AJ, Ryan, ND. In: DS, Charney. et al, eds. Neuropsychopharmacology. The Fifth Generation of Progress. Baltimore, MD: Lippincott Williams & Wilkins; 2002: 1081–1096.
6. Bauer, M, Whybrow, PC, Angst, J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry. 2002; 3(2):69–86.
7. Rush, AJ, Crismon, ML, Toprac, MG, et al. Consensus guidelines in the treatment of major depressive disorder. J Clin Psychiatry. 1998; 59(suppl 20):73–84.
8. Gabbard, GO, ed. Treatment of Psychiatric Disorders. 3rd ed. Vols. 1 and 2. Washington, DC; American Psychiatric Publishing, Inc; 2001.
9. Thase, ME, Howland, RH, Friedman, ES. Treating antidepressant non-responders with augmentation strategies: an overview. J Clin Psychiatry. 1998; 59(Suppl 5):5–12.
10. Price, LH, Chamey, DS. Delgado, PL, et al. Fenfluramine augmentation in tricyclic-refractory depression. J Clin Psychopharmacol. 1990; 10: 312–317.
11. Himmelhoch, JM, Detre, T, Kupfer, DJ, Swartzburg, M, Byck, R. Treatment of previously intractable depressions with tranylcypromine and lithium. J Nerv Ment Dis. 1972; 155(3):216–220.
12. Price, LH, Charney, DS, Heninger, GR. Efficacy of lithium-tranylcypromine treatment in refractory depression. Am J Psychiatry. 1985; 142: 619–623.
13. Fein, S, Paz, V, Rao, N, LaGrassa, J. The combination of lithium carbonate and an MAOI in refractory depressions. Am J Psychiatry. 1988; 145(2):249–250.
14. Dinan, TG. Lithium augmentation in sertraline-resistant depression: a preliminary dose-response study. Acta Psychiatr Scand. 1993; 88(4):300–301.
15. Baumann, P, Nil, R, Souche, A, et al. A double-blind, placebo-controlled study of Citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol. 1996; 16(4):307–314.
16. Fava, M. Rosenbaum, JF, Grossbard, SJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double blind, controlled study. Am J Psychiatry. 1994; 151: 1372–1374.
17. CLE, Katona, Abou-Saleh, MT, Harrison, DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry. 1995; 166: 80–86.
18. Salama, AA, Shafey, M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. Am J Psychiatry. 1989; 146(2):278.
19. Nelson, JC. Overcoming treatment tesistance in depression. J Clin Psychiatry. 1998; 59(Suppl 16):13–19.
20. Bauer, M, Adli, M, Baethge, C, et al. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. Can J Psychiatry. 2003; 48(7):440–448.
21. Gitlin, MJ, Weiner, H, Fairbanks, L, Hershman, JM, Friedfeld, N. Failure of T3 to potentiate tricyclic antidepressant response. J Affect Disord. 1987; 13: 267–272.
22. Nelson, JC. Treatment of antidepressant nonresponders: augmentation or switch? J Clin Psychiatry. 1998; 59(Suppl 15):35–41.
23. Marshall, RD, Liebowitz, MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol. 1996; 16(1):80–81.
24. Bodkin, JA, Lasser, RA, Wines, JD Jr, Gardner, DM, Baldessarini, RJ, Combining serotonin reuptake inhibitors and bupropion in partial responded to antidepressant monotherapy. J Clin Psychiatry. 1997; 58: 137–145.
25. Spier, SA. Use of bupropion with SRIs and venlafaxine. Depress Anxiety. 1998; 7(2):73–75.
26. Labbate, LA, Grimes, JB, Hines, A, et al. Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction. Ann Clin Psychiatry. 1997; 9: 241–245.
27. Ashton, AK, Rosen, RC. Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry. 1998; 59(3):112–115.
28. Young, SJ. Panic associated with combining fluoxetine and bupropion. J Clin Psychiatry. 1996; 57(4):177–178.
29. Seth, R, Jennings, AL, Bindman, J, Phillips, J, Bergmann, K. Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry. 1992; 161: 562–565.
30. Zajeckax, JM, Jeffries, H, Fawcett, J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J Clin Psychiatry. 1995; 56(8):338–343.
31. Nelson, JC, Mazure, CM, Bowers, MB Jr, Jatlow, PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991; 48(4):303–307.
32. Fava, M, JF, Rosenbaum. McGrath, PJ, Stewart, JW, Amsterdam, JD, Quitkin, FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994; 151(9):1372–1374.
33. Carpenter, LL, Yasmin, S, Price, LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002; 51(2):183–188.
34. Dam, J, Ryde, L, Svejso, J, Lauge, N, Lauritsen, B, Bech, P. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry. 1998; 31(2):48–54.
35. Menza, MA, Kaufman, KR, Castellanos, A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry. 2000; 61(5):378–381.
36. Hertel, P, Nomikos, GG, Schilstrom, B, Arborelius, L, Svensson, TH. Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of alpha 2-adrenoceptor antagonism. Neuropsychopharmacology. 1997; 17(1):44–55.
37. Szabo, ST, Blier, P. Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther. 2002; 302(3):983–991.
38. Wakade, CG, Mahadik, SP, Waller, JL, Chiu, FC. Atypical neuroleptics stimulate neurogenesis in adult rat brain. J Neurosci Res. 2002; 69(1):72–79.
39. Koch, S, Perry, KW, Bymaster, FP. Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentration in the rat. Neuropharmacology. 2004; 46(2):232–242.
40. Zhang, W, Perry, KW, Wong, DT, Potts, BD, Tollefson, GD, Bymaster, FP. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000; 23(3):250–262.
41. RC, Shelton, Tollefson, GD, Tohen, M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001; 158(1):131–134.
42. Corya, SA, Andersen, SW, Detke, HC, et al. Long term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open label study. J Clin Psychiatry. 2003; 64(11):1349–1356.
43. Parker, G. Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders. Int Clin Psychopharmacol. 2002; 17(2):87–89.
44. Papakostas, GI, TJ, Petersen, Nierenberg, AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004; 65(2):217–221.
45. Dunnet, DL, Amsterdam, JD, Shelton, RC, Hassman, H, Rosenthal, M, Romano, SJ. Adjunctive ziprasidone in treatment-resistant depression: pilot study. Presented at: Annual Meeting of the American College of Neuropsychopharmacology; 12, 2003; San Juan, Puerto Rico.
46. Ostroff, RB, Nelson, JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 1999; 69(4):256–259.
47. Tani, K, Takei, N, Kawai, M, et al. Augmentation of milnacipran by risperidone in treatment for major depression. Int J Neuropsychopharmacol. 2004; 7(1):55–58.
48. Adson, DE, Kushner, MG, Eiben, KM, Schulz, SC. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety. 2004; 19(2):121–126.
49. Worthington, J, Kinrys, G, Fava, M, Dording, C, Reese, H, Pollack, M. Aripiprazole as an augmentor of SSRIs in mood and anxiety disorder patients. Poster presented at: Annual Meeting of the New Clinical Drug Evaluation Unit; 6, 2004; Phoenix, AZ.
50. Keller, MB, McCullough, JP, Klein, DN, Arnow, B, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000; 342: 1462–1470.
51. Depression Guideline Panel. Depression in Primary Care. Vol. 2. Treatment of Major Depression. Clinical Practice Guideline. Rockville, MD: US Dept. of Health and Human Services, Agency for Health Care Policy and Research; AHCPR Publication No. 93-0551; 1993.
52. Nemeroff, CB, Heim, CM, Thase, ME, et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A. 2003; 100(24):14293–14296.
53. George, MS, Nahas, Z, Kozel, FA, Goldman, J, Molloy, M, Oliver, N. Improvement of depression following transcranial magnetic stimulation. Curr Psychiatry Rep. 1999; 1: 114–124.
54. PE, Holtzheimer 3rd, Russo, J, Avery, DH. A meta-analysis of repetitive transcranial magnetic stimulation in the tteatment of depression. Psychopharmacol Bull. 2001; 35(4):149–169.
55. Burt, T, Lisanby, SH, Sackeim, HA. Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. Int J Neuropsychopharmacol. 2002; 5(1):73–103.
56. Marangell, LB, Rush, AJ, George, MS, et al. Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry. 2002; 51: 280–287
57. Sackeim, HA, Rush, AJ, George, MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001; 25(5):713–728.
58. Stein, MB, Kline, NA, and JL, Matloff. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study. Am J Psychiatry. 2002; 159: 1777–1779.
59. Bartzokis, G, Freeman, T, Roca, V. Antipsychotic augmentation in patients with chronic combat-related post-traumatic stress disorder. Presented at: Annual Meeting of the New Clinical Drug Evaluation Unit; 6, 2001; Phoenix, AZ.
60. Hamner, MB, Deitsch, SE, Brodrick, PS, Ulmer, HG, Lorbetbaum, JP. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol. 2003; 23(1):15–20.
61. Sevincok, L, Topuz, A. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder. J Clin Psychopharmacol. 2003; 23(5):448–450.
62. Atmaca, M, Kuloglu, M, Tezcan, E, Gecici, O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol. 2002; 17(3):115–119.
63. CJ, McDougle. Epperson, CN, Pelton, GH, Wasylink, S, Price, LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000; 57: 794–801.
64. Brawman-Mintzer, O. Risperidone augmentation in treatment-resistant generalized anxiety disorder. Poster presented at; Annual Meeting of European College of Neuropsychopharmacology; 9 20-24, 2003; Prague, Czech Republic.
65. Caspi, A, Sugden, K, Moffitt, TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003; 301: 386–389.
66. Smeraldi, E, Zanardi, R, Benedetti, F, Di Bella, D, Perez, J, Catalano, M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998; 3(6):508–511.